Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Relapsed aggressive lymphomas are often treated with platinum-based chemotherapy (PBC) followed by an autologous stem cell transplant (ASCT). Response rates to PBC in patients with relapsed aggressive lymphomas are c. 60%, and non-responders have a dismal prognosis. Novel therapies for aggressive ly...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Westin, Jason R., McLaughlin, Peter, Romaguera, Jorge, Hagemeister, Fredrick B., Pro, Barbara, Dang, Nam H., Samaniego, Felipe, Rodriguez, Maria A., Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle, Fowler, Nathan, Nastoupil, Loretta, Feng, Lei, Loyer, Evelyn, Younes, Anas
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5279071/
https://ncbi.nlm.nih.gov/pubmed/25039868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires